News

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. 

Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company’s future. 

“I am honored to join Grenova at such an exciting time in the company’s journey,” said Hull. “Grenova is revolutionizing the way laboratories think about and use plastics—transforming single-use mindsets into sustainable, reusable solutions. I look forward to working closely with this talented team to continue driving meaningful change.” 

The addition to Grenova’s team is complemented by a new round of equity capital. The funding will be used to enhance Grenova’s automation portfolio, expand R&D capabilities, and grow the team to meet rising demand across global markets. The financing was led by Grenova investors, Peloton Equity and Hamilton Lane’s (Nasdaq: HLNE) Impact Fund II, along with other existing investors,  

“This investment affirms confidence in our vision and the market’s urgency to reduce plastic waste,” said Katherine Marrs, CEO of Grenova. “With this capital and Ted Hull on the board, we’re positioned to accelerate our mission to scale sustainable lab practices.” 

“We are excited to continue supporting Grenova’s growth,” said Ted Lundberg, Peloton Equity Managing Partner and Grenova’s Chairman. “We have worked with Ted Hull over the past 20 years and are thrilled to have him join Grenova. Ted brings a powerful blend of vision and experience that will help Grenova press its advantage as a category leader.” 

Backed by experienced leadership, a unique and patent protected product suite, strong investor confidence, and a clear vision, Grenova is working revolutionize laboratories worldwide. 

 

Read more here.

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin